FDA issues complete response letter for Replimune's melanoma drug

Replimune Group Inc. (REPL) received a Complete Response Letter from the FDA for its Biologics License Application for RP1 in advanced melanoma, citing concerns over the IGNYTE trial's design and insufficient evidence of effectiveness, though no safety issues were identified. Despite this regulatory setback and a significant Q1 2025 EPS miss, the company reported a robust cash position of $483.8 million, extending its runway into Q4 2026. Replimune plans to request a Type A meeting with the FDA to discuss a path forward for potential accelerated approval, with its stock showing resilience post-announcement.

Analysis

Replimune Group Inc. (REPL) has encountered a significant regulatory setback with the U.S. Food and Drug Administration's issuance of a Complete Response Letter (CRL) for its lead product candidate, RP1, in advanced melanoma. The FDA's rejection is not based on safety concerns but on the determination that the IGNYTE trial lacks substantial evidence of effectiveness and is difficult to interpret due to patient population heterogeneity. This development introduces considerable uncertainty into the approval timeline, directly contradicting the positive outlook that underpinned recent 'Overweight' and 'Buy' ratings from analysts at Piper Sandler, H.C. Wainwright, Cantor Fitzgerald, and JPMorgan, whose price targets ranged from $16 to $22. Compounding the negative news, the company reported a substantial first-quarter 2025 earnings miss with an EPS of -$3.07, far below the -$0.72 forecast. However, a critical mitigating factor is Replimune's robust financial position. The company's cash and equivalents have increased to $483.8 million, providing a cash runway into the fourth quarter of 2026. This financial buffer affords the company time to address the FDA's concerns, starting with a planned Type A meeting request, without the immediate pressure of seeking additional capital.

Key Decisions for Investors

• Investors should re-evaluate their thesis for REPL, as the CRL fundamentally delays the revenue timeline for its lead asset, RP1, and invalidates the core assumption behind recent bullish analyst ratings.
• Monitor the outcome of the upcoming Type A meeting with the FDA, as any clarity on a revised pathway for potential accelerated approval will be the most critical near-term catalyst for the stock.
• Consider the company's strong cash position, with a runway into late 2026, as a significant de-risking factor that provides the operational stability to navigate the extended regulatory process.
• The significant Q1 EPS miss should be noted as a point of concern regarding operational cash burn, though it is currently offset by the strong balance sheet.